Bal Harbour, Fla. - The use of topically applied immune response modifier imiquimod (Aldara) goes beyond its FDA-approved application for the treatment of genital and perianal warts.
Iovance Completes Biologics License Application (BLA) Submission for Advanced Melanoma Drug
The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques
5 Perspectives on Laser Treatment in Dermatology
The Cutaneous Connection: Using the Color Wheel to Discuss Nutrition
Adel Haque, MD, Provides His Best Advice for New Dermatologists
Recent Povorcitinib 2b Study Shows Improved Repigmentation